Enovis (NYSE:ENOV) Insider Oliver Engert Purchases 2,660 Shares of Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 2,660 shares of the company’s stock in a transaction on Friday, September 4th. The stock was bought at an average cost of $18.80 per share, with a total value of $50,008.00. Following the completion of the purchase, the insider owned 63,898 shares of the company’s stock, valued at approximately $1,201,282.40. The trade was a 4.34% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Wednesday, September 2nd, Oliver Engert acquired 2,458 shares of Enovis stock. The stock was purchased at an average price of $20.32 per share, with a total value of $49,946.56.
• On Thursday, September 3rd, Oliver Engert purchased 5,140 shares of Enovis stock. The shares were acquired at an average cost of $19.46 per share, with a total value of $100,024.40.
• On Monday, June 15th, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was bought at an average cost of $20.92 per share, for a total transaction of $20,920.00.
• On Thursday, June 11th, Oliver Engert purchased 1,200 shares of Enovis stock. The stock was bought at an average cost of $21.62 per share, with a total value of $25,944.00.
• On Wednesday, June 10th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were purchased at an average cost of $23.00 per share, for a total transaction of $23,000.00.

Enovis Price Performance

NYSE ENOV opened at $19.95 on Wednesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -1.04 and a beta of 1.31. The business has a 50 day simple moving average of $25.42 and a 200 day simple moving average of $24.18. Enovis Corporation has a 52-week low of $18.52 and a 52-week high of $34.28.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same quarter last year, the firm earned $0.79 EPS. Enovis’s revenue for the quarter was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Institutional Trading of Enovis

A number of hedge funds have recently made changes to their positions in ENOV. IFP Advisors Inc lifted its stake in shares of Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after acquiring an additional 1,174 shares during the period. Arax Advisory Partners bought a new position in Enovis during the 4th quarter worth approximately $29,000. Allworth Financial LP bought a new position in Enovis during the 2nd quarter worth approximately $36,000. EverSource Wealth Advisors LLC lifted its position in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Enovis in the 2nd quarter valued at $48,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ENOV. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. UBS Group reissued a “buy” rating and set a $51.00 price target (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Citigroup restated a “market outperform” rating on shares of Enovis in a research note on Wednesday, September 2nd. Wall Street Zen cut Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Wells Fargo & Company dropped their target price on Enovis from $39.00 to $33.00 and set an “overweight” rating for the company in a report on Wednesday, September 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and a consensus price target of $40.38.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.